home > ict > autumn 2012 > thinking allowed
International Clinical Trials

Thinking Allowed

Elena Logan of PPD talks to ICT about her guiding business philosophy, and highlights the need for a greater emphasis on strategic relationships in 2013

ICT: What was your entry point into the clinical trials industry?

Elena Logan: I started my career with a large pharmaceutical company, so my introduction to clinical research came when I accepted a position in the clinical supplies group. I literally had no idea what clinical trials were, but it sounded interesting, and I certainly didnít recognise the career potential in this business.

Which part of your current role do you most enjoy?

Without question, the best part of my job is the people that I work with. I am fortunate to be surrounded by such a fantastic group of diverse, highly committed professionals worldwide. I really enjoy a challenge, especially those we face as a service provider as we constantly look for ways to be innovative and stimulate an entrepreneurial culture.

Which part is the most challenging?

The most significant challenge I face is trying to strike a balance. In business, we serve a large number of clients, and we are focused on meeting their needs. So itís critical that everyone understands those dynamics and shares our desire to provide the highest possible level of service.

How would you describe your business philosophy?

My general philosophy is that a leader who takes care of her employees also takes care of her customers. Our people drive the success of our company, so itís important to recognise the important role they play and provide opportunities for them to succeed.

What has been your proudest moment?

Celebrating employee successes has been extremely fulfilling to me. For instance, I was able to play a positive role in a young womanís career. She began in customer service and worked hard to develop her strengths. As a result she blossomed into an excellent leader.

And your greatest disappointment?

Iím a highly competitive person. Since I am motivated by sharing in the accomplishments of those around me, anytime we arenít able to celebrate a win, I look for ways to secure success the next time.

When are you happiest?

I was raised in a very traditional family, so I am happiest when my entire family is together sharing a meal. In business, I get the greatest pleasure from helping an organisation and its people to grow. Seeing the successes that result creates great fulfilment for me.

What keeps you awake at night?

One of the things Iíve learnt is that you donít accomplish much worrying over things you canít control. While I certainly take all business concerns seriously, I view them as challenges rather than as a source of concern.

What do you think the clinical trials sector needs to focus on in 2013?

Relationships and service. Iíd like to see a greater emphasis on strategic relationships in which both service providers and sponsors can have an active, ongoing investment in the partnership, rather than on transactional relationships. As providers and as an industry, we should strive to enhance our relationships with sponsors and the service we provide them.

How do you think the industry will change over the next 10 years?

Targeted therapies are going to play a significant role in patient care. Pharma and biotech companies are doing some exciting work in discovering and developing personalised medicines and companion diagnostics. Service providers and sponsors are going to have to work even more collaboratively in order to develop these medicines and diagnostics effectively and efficiently. I look forward to working with our clients in that way, helping bring important, safe medicines to patients.

What is the most important lesson you have learnt?

Hard work, perseverance and good timing can pay great dividends. But, as I noted earlier, our employees are our greatest asset, and we should never underestimate their value to our customers, our company and us personally. If you communicate with them and take care of them, they will be successful and you will, too!


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Elena Logan is Senior Vice President of Global Central Labs at PPD. She has more than 25 years of experience in laboratory services, operations, quality assurance, sales, business development and strategic planning in the pharmaceutical and contract research industries.




Elena Logan
Print this page
Send to a friend
Privacy statement
News and Press Releases


More info >>

White Papers

Conveying Medical Guidance in Clinical Trials Ė A Survey

Europital Medical Consultancy

With the incremental demand for proactive safety surveillance throughout the conduct of clinical trials, the role of Medical Management is at the fore in ensuring the safety and wellbeing of the participants. The complex responsibilities of a Medical Monitor (MM) starts from the design and development phase, through to study close out. Understanding the principle behind the protocol and the prospective medical solution the study would deliver forms the bloodline for the MM role. Often, the MM is the face of contact for both the site personnel and the study team members with regard to medical, safety and scientific issues within the project. When it comes to medical guidance, the communication channel used to deliver solutions contributes to a large extent in effectively managing decisive situations. Our previous study on acquiring medical guidance from an operations team perspective revealed that e-mails were the most used communication method (see the article, 'Talking Points', in ICT November 2014). In our efforts to further strengthen the mode of medical guidance delivery, we designed a survey to study the existing trend and constraints in this communication chain management, as outlined here.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement